Nothing Special   »   [go: up one dir, main page]

Angelini et al., 2021 - Google Patents

The use of lateral flow immunoassays for the detection of fentanyl in seized drug samples and postmortem urine

Angelini et al., 2021

View HTML
Document ID
16227167776601683856
Author
Angelini D
Biggs T
Prugh A
Smith J
Hanburger J
Llano B
Avelar R
Ellis A
Lusk B
Malik Naanaa A
Sisco E
Sekowski J
Publication year
Publication venue
Journal of forensic sciences

External Links

Snippet

The opioid crisis has continued to progress in the United States and the rest of the world. As this crisis continues, there is a pressing need for a rapid and cost‐effective method for detecting fentanyl. Recent studies have suggested that lateral flow immunoassays (LFIs) …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/543—Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/26—Investigating or analysing materials by specific methods not covered by the preceding groups oils; viscous liquids; paints; inks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Similar Documents

Publication Publication Date Title
Lockwood et al. High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips
Harper et al. An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services
Philp et al. A review of chemical ‘spot’tests: A presumptive illicit drug identification technique
Angelini et al. The use of lateral flow immunoassays for the detection of fentanyl in seized drug samples and postmortem urine
Kennedy et al. Rapid analysis of fentanyls and other novel psychoactive substances in substance use disorder patient urine using paper spray mass spectrometry
Swortwood et al. Cross‐reactivity of designer drugs, including cathinone derivatives, in commercial enzyme‐linked immunosorbent assays
Ellefsen et al. Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology
Reisfield et al. Rational use and interpretation of urine drug testing in chronic opioid therapy
Palamar et al. Drug checking to detect fentanyl and new psychoactive substances
Krotulski et al. Emerging synthetic cannabinoids: development and validation of a novel liquid chromatography quadrupole time-of-flight mass spectrometry assay for real-time detection
Angelini et al. Evaluation of a lateral flow immunoassay for the detection of the synthetic opioid fentanyl
Kulig Interpretation of workplace tests for cannabinoids
Grafinger et al. Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication
Krotulski et al. Sample mining and data mining: combined real‐time and retrospective approaches for the identification of emerging novel psychoactive substances
Elkins et al. Colour quantitation for chemical spot tests for a controlled substances presumptive test database
Baumann et al. Novel synthetic opioids and overdose deaths: tip of the iceberg?
Leonard et al. Inter-and intra-assay reproducibility of microplate Alamar blue assay results for isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tuberculosis
Marchei et al. Ultra-high performance liquid chromatography-high resolution mass spectrometry and high-sensitivity gas chromatography-mass spectrometry screening of classic drugs and new psychoactive substances and metabolites in urine of consumers
Schackmuth et al. Immunoassay-based detection of fentanyl analogs in forensic toxicology
Puzyrenko et al. Urine drug screening in the era of designer benzodiazepines: comparison of three immunoassay platforms, LC–QTOF-MS and LC–MS-MS
Olivieri et al. Determining the effects of adulterants on drug detection via enzyme‐linked immunosorbent assay and adulterant tests strips
Cone et al. Urine toxicology testing in chronic pain management
Picó et al. Mass spectrometry in wastewater-based epidemiology for the determination of small and large molecules as biomarkers of exposure: toward a global view of environment and human health under the COVID-19 outbreak
Köhler et al. Evaluation of CEDIA and DRI drugs of abuse immunoassays for urine screening on a Thermo Indiko Plus analyzer
Sisco et al. Identification of the veterinary sedative medetomidine in combination with opioids and xylazine in Maryland